|Articles|September 1, 2003

September 2003
Volume 9
Issue 9

Validation of Data Collection for the HEDIS Performance Measure on Chlamydia Screening in an MCO

Author(s)Feifei Wei, PhD, Cathleen M. Walsh, DrPH, MSPH

Download PDF: Validation of Data Collection for the HEDIS Performance Measure on Chlamydia Screening in an MCO

Articles in this issue

almost 23 years ago

Article

Improvements in Access to Care for HIV and AIDS in a Statewide Medicaid Managed Care System

almost 23 years ago

Article

Effects of Protocol-Driven Care Versus Usual Outpatient Clinic Care on Survival Rates in Patients With Type 2 Diabetes

almost 23 years ago

Article

The Public's Opinions of Physicians: Do Perceived Choice and Exercised Choice Matter?

almost 23 years ago

Article

The Effect of HMO Competition on Gatekeeping, Usual Source of Care, and Evaluations of Physician Thoroughness

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

ByJulie A. Patterson, PharmD, PhD,Roswell A. Cole, PharmD, MPH,Jonathan D. Campbell, PhD, MS,John Michael O’Brien, PharmD, MPH

July 9th 2026

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

ByVivian T. E. Tar, PharmD, MBA

July 8th 2026

Readability of Hospital Patient Financial Policy Documents

BySamantha Randall, BA,Sumedha Raghu, MS,Ella Cho,Nina Linh Nguyen, MHA,Erin Trish, PhD,Erin L. Duffy, PhD, MPH

July 7th 2026

Validation of Data Collection for the HEDIS Performance Measure on Chlamydia Screening in an MCO

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Validation of Data Collection for the HEDIS Performance Measure on Chlamydia Screening in an MCO

Articles in this issue

Related Content

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Upper Payment Limit Implementation Risks for Patients, Pharmacies, and Providers

The New Oncology Blueprint: Integrating Clinical Intelligence for Sustainable Value

Readability of Hospital Patient Financial Policy Documents

Trending on AJMC

Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues

Upcoming 2026 FDA Decisions Could Expand Treatment Options Across Oncology and Hepatitis B

FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer